Sequenom (NASDAQ:SQNM) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 3 by 4 Brokerage Firm. 4 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. Equity Analysts at the Ladenburg Thalmann upgrades the rating on Sequenom (NASDAQ:SQNM). The brokerage firm has issued a Neutral rating on the shares. The shares were previously rated Sell. The rating by the firm was issued on March 3, 2016.
Sequenom (NASDAQ:SQNM): 3 Analyst have given the stock of Sequenom (NASDAQ:SQNM) a near short term price target of $1.43. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $0.5. The higher price target estimate is at $2 while the lower price estimates are fixed at $1.
Sequenom (NASDAQ:SQNM) witnessed a decline in the market cap on Tuesday as its shares dropped 3.36% or 0.04 points. After the session commenced at $1.2, the stock reached the higher end at $1.21 while it hit a low of $1.11. With the volume soaring to 1,353,985 shares, the last trade was called at $1.15. The company has a 52-week high of $3.31. The company has a market cap of $137 million and there are 119,216,003 shares in outstanding. The 52-week low of the share price is $0.9153.
Shares of Sequenom Inc. rose by 6.48% in the last five trading days and 9.52% for the last 4 weeks. Sequenom Inc. has dropped 23.84% during the last 3-month period . Year-to-Date the stock performance stands at -29.88%.
Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Companys diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.